The global humanized mice model market was valued at USD 155 million in 2025. The market is projected to grow from USD 172 million in 2026 to USD 298.5 million by 2034, exhibiting a compound annual growth rate of 7.14% during the forecast period. Contrive Datum Insights presents this information in its report titled "Humanized Mice Model Market Size, Share & Industry Analysis, By Type (Humanized Mouse Models, Humanized Rat Models), Application (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions), Humanization technology (PBMC Humanization, Hematopoietic Stem Cell (HSC) Humanization, Genetically Engineered (Knock-in) Humanization), Research application (Oncology & Immuno-Oncology, Infectious Disease Research, Immunology & Autoimmune Disease Research, Toxicology & Pharmacokinetics, Others), Product & service type (Off-the-Shelf/Catalog Models, Custom Model Development Services, Related Support Services), and Regional Forecast, 2026-2034".
A humanized mouse or rat model is a laboratory animal engineered to carry components of the human immune system, such as human hematopoietic stem cells, peripheral blood mononuclear cells, or specific human genes inserted through genetic modification, so that its biological responses more closely mirror those of a human patient. These models are used to study how a human immune system interacts with a disease, a pathogen, or a candidate drug before that drug reaches human trials. Buyers include pharmaceutical and biotechnology companies developing oncology and immunology therapies, contract research organizations running preclinical studies on behalf of drug sponsors, and academic and government research institutions studying immune biology and infectious disease.
Rising adoption of humanized mouse and rat models in immuno-oncology drug development
Rising adoption of humanized mouse and rat models in immuno-oncology drug development is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.14% a year, the type lines exposed to it move fastest: Humanized Rat Models compounds at 11.93%, taking its share of revenue from 12% to 18% and its value from USD 18.6 million to USD 53.7 million.
On the upside, the study's bull case assumes the bull case assumes faster adoption of humanized models by contract research organizations and quicker translation of current immuno-oncology pipelines into funded preclinical programs, particularly across Asia Pacific, which would take 2034 revenue to USD 340.3 million rather than the USD 298.5 million base case.
However, the bear case assumes tighter biotechnology funding and slower conversion of early-stage immuno-oncology and cell therapy pipelines into funded preclinical studies, delaying purchases of humanized models across all regions, which would hold 2034 revenue to USD 262.7 million. Humanized Mouse Models, which carries 88% of 2025 revenue, already grows at only 6.3% against the market's 7.14%, so the largest part of the base is also its slowest.
Key Players Compete on Humanized Mouse Models Volume and Humanized Rat Models Growth
Competition in the global humanized mice model market runs along the type axis rather than the regional one. Humanized Mouse Models holds 88% of 2025 revenue at USD 136.4 million and remains the largest line through 2034 at 82%, making it the position hardest for a challenger to take. Humanized Rat Models, growing at 11.93%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 155 million.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Humanized Mouse Models | 88% · USD 136.4 million | — |
| Application | Pharmaceutical & Biotechnology Companies | 52% · USD 80.6 million | Contract Research Organizations 9.24% |
| Humanization technology | PBMC Humanization | 45% · USD 69.8 million | Genetically Engineered (Knock-in) Humanization 10.71% |
| Research application | Oncology & Immuno-Oncology | 46% · USD 71.3 million | Infectious Disease Research 9.98% |
| Product & service type | Off-the-Shelf/Catalog Models | 58% · USD 89.9 million | Custom Model Development Services 10.08% |
- Based on regional analysis, North America led the global humanized mice model market in 2025 with 45% of global revenue at USD 69.7 million, reaching USD 119.4 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 29% in 2034, with revenue growing from USD 34.1 million to USD 86.6 million.
- Middle East and Africa remains the smallest region throughout, at 3.5% of 2025 revenue and 4% by 2034.
- Humanized Rat Models is projected to grow at 11.93% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 61.3 million in 2025, 39.5% of global revenue.
The report segments the market across five axes; by type, and by application, humanization technology, research application and product & service type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 262.7 million and USD 340.3 million by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.